Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya ...

Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

The FDA approved Tremfya in September 2024 for moderately to severely active ulcerative colitis. The application for moderately to severely active Crohn's disease is currently under FDA review.

The anti-IL-23 monoclonal antibody, called picankibart, was shown to clear or nearly clear all lesions after 16 weeks among 48.2% of the 82 participating Chinese patients that were classified as ...

Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.

(RTTNews) - Johnson & Johnson (JNJ) Monday announced positive results from Phase 3 GRAVITI study of Tremfya as both induction and maintenance therapy in Crohn's disease, a type of inflammatory ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

Tremfya (guselkumab) is a prescription drug that’s used to treat certain autoimmune conditions, including plaque psoriasis. Tremfya can cause side effects that range from mild to serious.